Calliditas Therapeutics AB (Calliditas Therapeutics AB) Total Assets : $181.26 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Total Assets?

Calliditas Therapeutics AB's Total Assets for the quarter that ended in Dec. 2023 was $181.26 Mil.

During the past 12 months, Calliditas Therapeutics AB's average Total Assets Growth Rate was 25.80% per year. During the past 3 years, the average Total Assets Growth Rate was 23.70% per year. During the past 5 years, the average Total Assets Growth Rate was 180.40% per year.

During the past 9 years, Calliditas Therapeutics AB's highest 3-Year average Total Assets Growth Rate was 508.20%. The lowest was -8.90%. And the median was 154.00%.

Total Assets is connected with ROA %. Calliditas Therapeutics AB's annualized ROA % for the quarter that ended in Dec. 2023 was -4.39%. Total Assets is also linked to Revenue through Asset Turnover. Calliditas Therapeutics AB's Asset Turnover for the quarter that ended in Dec. 2023 was 0.27.

Calliditas Therapeutics AB Total Assets Historical Data

The historical data trend for Calliditas Therapeutics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Total Assets Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

89.61

175.04

160.61

188.18

181.26

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															139.15	188.18	158.71	145.42	181.26

Calliditas Therapeutics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Calliditas Therapeutics AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	32.64	+	148.616
	=	181.26

Calliditas Therapeutics AB's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	32.64	+	148.616
	=	181.26

Calliditas Therapeutics AB (NAS:CALT) Total Assets Explanation

Total Assets is connected with ROA %.

Calliditas Therapeutics AB's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-7.164	/	( (145.415	+	181.255)	/ 2 )
	=	-7.164	/	163.335
	=	-4.39 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Calliditas Therapeutics AB's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	44.022	/	( (145.415	+	181.255)	/ 2 )
=	44.022	/	163.335
=	0.27

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Calliditas Therapeutics AB Total Assets Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.